Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Outsourcing IMP production - a modern twist on a classic tal...

Mike Parry shares his words of wisdom on the hard and soft criteria to consider when choosing a contract manufacturing organisation to deliver a project. Having worked in the pharmaceutical manufacturing sector for many years, I have read a lot of literature about ‘how to choose a...

Articles

Healthcare market research on the brink of a second revoluti...

Henry Gazay discusses the increasing use of mobile technology, such as smartphones, within the healthcare industry, and how this can be a great tool for market research. No, I don’t have a crystal ball, but I have long had a fascination with computer technology, and quite early on...

Articles

“Pay for delay” situation improves but European Commission c...

Paul Gershlick highlights results from a recent report suggesting that the ‘pay for delay’ situation is improving but continues to be a concern. With any form of intellectual property rights protection, a balance is struck between enabling free competition for the benefit of consumers …

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access